News | Heart Valve Technology | October 14, 2015

Boston Scientific Announces Additional Investment And Right To Acquire MValve Technologies

Investment will be partly used to fund first-in-human clinical trial for MValve TMVR docking system with Boston Scientific’s Lotus valve

Boston Scientific, investment, MValve Technologies, first-in-human clinical trial, TMVR, Lotus Valve

October 14, 2015 — Boston Scientific Corp. announced it has closed on an additional round of financing with MValve Technologies Ltd., developer of a percutaneous mitral valve replacement system designed to work with the Boston Scientific Lotus Valve. Boston Scientific has provided the company with funding since 2012 and has an exclusive option to acquire MValve.

MValve Technologies plans to utilize the new financing, in part, to fund a first-in-human clinical trial for the MValve docking system for transcatheter mitral valve replacement (TMVR) in patients with mitral regurgitation. The approach, in which the Boston Scientific Lotus Valve is deployed inside the MValve docking system, is designed to enable the treatment of mitral regurgitation in a broad range of patients, and to improve long-term clinical outcomes in this patient population. Both the dock and valve can be repositioned and recaptured, enabling precise valve placement and physician confidence prior to releasing.

Mitral regurgitation is the most common type of heart valve disorder and occurs when the mitral valve does not close properly, causing an abnormal reversal of blood to flow from the left ventricle into the left atrium.

The Lotus Aortic Valve System is a differentiated second-generation valve replacement technology, consisting of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for guidance and percutaneous placement of the valve. The low-profile delivery system is designed to enable predictable and precise placement associated with early valve function, as well as bi-directional atraumatic repositioning and retrieval at any time prior to release of the aortic valve implant. The device also features a unique Adaptive Seal designed to minimize the incidence of paravalvular regurgitation.

In the United States, the Lotus Valve System is an investigational device and not available for sale. It is CE marked in the European Union.

For more information: www.bostonscientific.com


Related Content

News | Structural Heart

On July 16, Diagnostic and Interventional Cardiology will present a webinar on "Maximizing Structural Heart Workflows ...

Home July 08, 2024
Home
News | Structural Heart

July 3, 2024 — Jon Kobashigawa, MD, director of the Heart Transplant Program in the Department of Cardiology in the ...

Home July 03, 2024
Home
News | Structural Heart

June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program, reinforcing the positive ...

Home June 07, 2024
Home
News | Structural Heart

April 25, 2024 — Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using ...

Home April 25, 2024
Home
News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
Subscribe Now